



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

PERREAULT, Jean-Pierre et al.

Serial No. 09/699,667

Filed: October 30, 2000

**For: NUCLEIC ACID ENZYME FOR
RNA CLEAVAGE**

) **Group Art Unit: 1635**

) **Examiner: J. Zara**

PATENT

258/238

#8/K/5/23
CPR
RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Washington, D.C. 20231

Attention: Office of Initial Patent Examination's
Customer Service Center

Applicant respectfully requests that a corrected Filing Receipt issue for the above-identified application. The Updated Filing Receipt issued by the U.S. Patent and Trademark Office on March 26, 2001 does not reflect the correct city and state for the Inventor Sirinart Ananvoranich. The correct information, which was previously submitted in the Combined Declaration and Power of Attorney that was mailed with the Transmittal of Missing Parts on March 16, 2001 (copies of

CERTIFICATE OF MAILING

(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

April 25, 2002
Date of Deposit
LA-234526.1

Laura Murphy

Name of Person Mailing Paper

Signature of Person Mailing Paper


Updated Filing Receipt and Declaration are enclosed), should reflect the address of Inventor Sirinart Ananvoranich as Harrow, Canada instead of Westbury, Canada. Please correct the filing receipt to include the previously submitted information.

Applicant believes that no fee is necessary at this time. However, if any fees are associated with this request, the Commissioner is authorized to charge the necessary amount from Lyon & Lyon LLP's Deposit Account No. 12-2475.

Respectfully submitted,
LYON & LYON LLP

Dated: April 25, 2002

By:



Lois M. Kwasigroch
Reg. No. 35,579



22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP
633 W. Fifth Street, Suite 4700
Los Angeles, CA 90071
phone: (213) 489-1600
fax: (213) 955-0440



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED page 1 of 4

MAY 23 2002

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/699,667	10/30/2000	1635	420	77473-12	7	19	1

22249
LYON & LYON LLP
SUITE 4700
633 WEST FIFTH STREET
LOS ANGELES, CA 90071-2066

258/235

FILING RECEIPT



OC000000005904604

Date Mailed: 03/26/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jean-Pierre Perreault, Fleurimont, CANADA;
Sirinart Ananvoranich, Westbury, CANADA;
Daniel Lafontaine, Saint-Alexis de Montcalm, CANADA;COPY OF PAPERS
ORIGINALLY FILED

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CON OF PCT/CA99/00391 04/29/1999

Foreign Applications

CANADA 2230203 04/29/1998

If Required, Foreign Filing License Granted 01/19/2001

** SMALL ENTITY **

Title

Nucleic acid enzyme for RNA cleavage

RECEIVED

MAY 23 2002

U.S. PROSECUTION

Preliminary Class

435

Data entry by : BROWN, ROSCOE

Team : OIPE

Date: 03/26/2001



LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



PATENT
258/238

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

In re the Application of:

PERREAULT, Jean-Pierre et al.

Serial No. 09/699,667

Filed: October 30, 2000

**For: NUCLEIC ACID ENZYME FOR
RNA CLEAVAGE**

Group Art Unit: 1635

Examiner: J. Zara

STATUS INQUIRY

Box No Fee
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Inquiry is respectfully made as to the status of the above-identified application. Applicant has received no communication from the United States Patent and Trademark Office since receiving the DNA Sequence Requirement mailed 07/02/01. Submission of the Substitute Sequence Listing was mailed to the PTO on August 2, 2001.

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

April 25, 2002
Date of Deposit
LA-234524.1

Laura Murphy

Name of Person Mailing Paper

Laura Murphy
Signature of Person Mailing Paper

Kindly advise the undersigned of the present status of this application by responding below.


A stamped return-addressed envelope is provided.

No fee is believed due in connection with this communication. If any fee is required,
however, please charge Lyon & Lyon's Deposit Account No. 12-2475 for the appropriate amount.

Respectfully submitted,
LYON & LYON LLP

Dated: April 25, 2002

By: _____


Lois M. Kwasigroch
Reg. No. 35,579



LYON & LYON LLP
633 W. Fifth Street, Suite 4700
Los Angeles, CA 90071
phone: (213) 489-1600
fax: (213) 955-0440

STATUS INQUIRY REPLY

APPLICATION SERIAL NO. 09/699,667 IS CURRENTLY _____



RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

Please acknowledge receipt of the following by affixing hereon the Patent and Trademark Office date stamp and returning this card to our office.

Applicant: PERREAULT et al.
Serial No.: 09/699,667
For: NUCLEIC ACID ENZYME FOR RNA CLEAVAGE
Filed: March 16, 2001



Title of Document: TRANSMITTAL OF MISSING PARTS

Attorney(s): Carol A. Schneider
Docket No.: 258/235
Enclosures: Combined Declaration and Power of Attorney; Copy of Notice To File Missing Parts of Nonprovisional Application; Check No. 13694 for \$65.00 (surcharge fee for Declaration)

Date of Mailing: March 16, 2001